Sponsor:
University of Alberta
Code:
NCT05923970
Conditions
Vaccination Failure
Vaccine Response Impaired
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serology for antibody levels - Baseline
Serology to assess cell mediated immune (CMI) response - Baseline
Serology for antibody levels - Post third dose of MMR vaccine
Serology to assess CMI - Post third dose of MMR vaccine
Brief summary:
Conditions
Vaccination Failure
Vaccine Response Impaired
Study ID
NCT05923970
Start date
Nov 9, 2024
Status verified date
Mar, 2026
Completion date
Sep 30, 2027
Anticipated
Primary completion date
Sep 30, 2027
Anticipated
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
200 participants
Anticipated
Arms
Women with low rubella antibodies
Women with high rubella antibodies
Interventions
Serology for antibody levels - Baseline
Serology to assess cell mediated immune (CMI) response - Baseline
Serology for antibody levels - Post third dose of MMR vaccine
Serology to assess CMI - Post third dose of MMR vaccine
Primary outcome measure
Central contacts
Locations
University of Alberta
Recruiting
Edmonton, Alberta, Canada, T6G2R3
Contacts
Sponsor
University of Alberta
Last update posted
Mar 16, 2026
Last verified
Mar, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Alberta on 2026-03-16.